HDAC inhibitors induce histone hyperacetylation by a relative increase of histone
acetyltransferase activity. Histone hyperacetylation may affect chromatin structure and …

Protein/peptide-mediated gene delivery has recently emerged as a powerful approach in
non-viral gene transfer. In previous studies, we and other groups found that histones …

All-trans retinoic acid (RA) causes differentiation of neuroblastoma cells, and retinoids have
been used in clinical trials in children with advanced neuroblastoma. Combination of RA …

Trichostatin A (TSA), originally developed as an antifungal agent, is one of potent histone
deacetylase (HDAC) inhibitors, which are known to cause growth arrest and apoptosis …

Current chemotherapy regimens are comprised mostly of single-target drugs which are often
plagued by toxic side effects and resistance development. A pharmacological strategy for …

Alterations in histone acetylation status have been implicated in carcinogenesis. Histone
deacetylase inhibitors, such as suberoylanilide hydroxamic acid (SAHA), can potentially …

Multidrug resistance (MDR) mediated by the ATP‐dependent efflux protein P‐glycoprotein
(P‐gp) is a major obstacle to the successful treatment of many cancers. In addition to …

Fas-mediated apoptosis plays an important role in elimination of tumor cells in vivo, but
some tumor-derived cells are resistant to this mechanism. Here, we show that treatment with …

The invention relates to the inhibition of histone deacety lase. The invention provides
compounds and methods for inhibiting histone deacetylase enzymatic activity. The inven …

Histone deacetylase inhibitors (HDIs) are a promising new class of antineoplastic agents
with the ability to induce apoptosis and growth arrest of cancer cells. In addition, HDIs have …